KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer

Jian Ming Xu, Xiao Jing Liu, Fei Jiao Ge, Li Lin, Yan Wang, Manish R. Sharma, Ze Yuan Liu, Stefania Tommasi, Angelo Paradiso

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

BACKGROUND: The optimal laboratory assay for detecting KRAS mutations in different biospecimens from patients with metastatic colorectal cancer (mCRC), and the clinical relevance of these gene alterations is still in question. We analyzed the prognostic-predictive relevance of KRAS status, determined in tumor and plasma DNA by two different assays, in a large mono-institutional series of mCRC patients.

METHODS: DNA sequencing and peptide-nucleic-acid-mediated-polymerase chain reaction clamping (PNA-PCR) were used to determine KRAS status in 416 tumor and 242 matched plasma DNA samples from mCRC patients who received chemotherapy only. Relationships with outcomes were analyzed with respect to the different assays and tissue types.

RESULTS: PNA-PCR was significantly more sensitive in detecting KRAS mutations than sequencing (41% vs. 30%, p 

CONCLUSIONS: KRAS mutation status is of prognostic relevance in patients with mCRC. KRAS mutations in both tumor tissue and plasma are a strong prognostic marker for poor outcomes.

Original languageEnglish
Pages (from-to)104
Number of pages1
JournalJournal of Experimental and Clinical Cancer Research
Volume33
DOIs
Publication statusPublished - 2014

Fingerprint

Colorectal Neoplasms
Peptide Nucleic Acids
Mutation
Survival
Constriction
Neoplasms
Polymerase Chain Reaction
DNA
DNA Sequence Analysis
Drug Therapy
Genes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer. / Xu, Jian Ming; Liu, Xiao Jing; Ge, Fei Jiao; Lin, Li; Wang, Yan; Sharma, Manish R.; Liu, Ze Yuan; Tommasi, Stefania; Paradiso, Angelo.

In: Journal of Experimental and Clinical Cancer Research, Vol. 33, 2014, p. 104.

Research output: Contribution to journalArticle

@article{3bf1536cbeec4352a1e4addfca9fcc16,
title = "KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer",
abstract = "BACKGROUND: The optimal laboratory assay for detecting KRAS mutations in different biospecimens from patients with metastatic colorectal cancer (mCRC), and the clinical relevance of these gene alterations is still in question. We analyzed the prognostic-predictive relevance of KRAS status, determined in tumor and plasma DNA by two different assays, in a large mono-institutional series of mCRC patients.METHODS: DNA sequencing and peptide-nucleic-acid-mediated-polymerase chain reaction clamping (PNA-PCR) were used to determine KRAS status in 416 tumor and 242 matched plasma DNA samples from mCRC patients who received chemotherapy only. Relationships with outcomes were analyzed with respect to the different assays and tissue types.RESULTS: PNA-PCR was significantly more sensitive in detecting KRAS mutations than sequencing (41{\%} vs. 30{\%}, p CONCLUSIONS: KRAS mutation status is of prognostic relevance in patients with mCRC. KRAS mutations in both tumor tissue and plasma are a strong prognostic marker for poor outcomes.",
author = "Xu, {Jian Ming} and Liu, {Xiao Jing} and Ge, {Fei Jiao} and Li Lin and Yan Wang and Sharma, {Manish R.} and Liu, {Ze Yuan} and Stefania Tommasi and Angelo Paradiso",
year = "2014",
doi = "10.1186/s13046-014-0104-7",
language = "English",
volume = "33",
pages = "104",
journal = "Journal of Experimental and Clinical Cancer Research",
issn = "0392-9078",
publisher = "BioMed Central Ltd.",

}

TY - JOUR

T1 - KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer

AU - Xu, Jian Ming

AU - Liu, Xiao Jing

AU - Ge, Fei Jiao

AU - Lin, Li

AU - Wang, Yan

AU - Sharma, Manish R.

AU - Liu, Ze Yuan

AU - Tommasi, Stefania

AU - Paradiso, Angelo

PY - 2014

Y1 - 2014

N2 - BACKGROUND: The optimal laboratory assay for detecting KRAS mutations in different biospecimens from patients with metastatic colorectal cancer (mCRC), and the clinical relevance of these gene alterations is still in question. We analyzed the prognostic-predictive relevance of KRAS status, determined in tumor and plasma DNA by two different assays, in a large mono-institutional series of mCRC patients.METHODS: DNA sequencing and peptide-nucleic-acid-mediated-polymerase chain reaction clamping (PNA-PCR) were used to determine KRAS status in 416 tumor and 242 matched plasma DNA samples from mCRC patients who received chemotherapy only. Relationships with outcomes were analyzed with respect to the different assays and tissue types.RESULTS: PNA-PCR was significantly more sensitive in detecting KRAS mutations than sequencing (41% vs. 30%, p CONCLUSIONS: KRAS mutation status is of prognostic relevance in patients with mCRC. KRAS mutations in both tumor tissue and plasma are a strong prognostic marker for poor outcomes.

AB - BACKGROUND: The optimal laboratory assay for detecting KRAS mutations in different biospecimens from patients with metastatic colorectal cancer (mCRC), and the clinical relevance of these gene alterations is still in question. We analyzed the prognostic-predictive relevance of KRAS status, determined in tumor and plasma DNA by two different assays, in a large mono-institutional series of mCRC patients.METHODS: DNA sequencing and peptide-nucleic-acid-mediated-polymerase chain reaction clamping (PNA-PCR) were used to determine KRAS status in 416 tumor and 242 matched plasma DNA samples from mCRC patients who received chemotherapy only. Relationships with outcomes were analyzed with respect to the different assays and tissue types.RESULTS: PNA-PCR was significantly more sensitive in detecting KRAS mutations than sequencing (41% vs. 30%, p CONCLUSIONS: KRAS mutation status is of prognostic relevance in patients with mCRC. KRAS mutations in both tumor tissue and plasma are a strong prognostic marker for poor outcomes.

UR - http://www.scopus.com/inward/record.url?scp=84965191195&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84965191195&partnerID=8YFLogxK

U2 - 10.1186/s13046-014-0104-7

DO - 10.1186/s13046-014-0104-7

M3 - Article

C2 - 25491325

AN - SCOPUS:84965191195

VL - 33

SP - 104

JO - Journal of Experimental and Clinical Cancer Research

JF - Journal of Experimental and Clinical Cancer Research

SN - 0392-9078

ER -